243 related articles for article (PubMed ID: 26321082)
21. Advances in immunotherapy for the treatment of glioblastoma.
Tivnan A; Heilinger T; Lavelle EC; Prehn JH
J Neurooncol; 2017 Jan; 131(1):1-9. PubMed ID: 27743144
[TBL] [Abstract][Full Text] [Related]
22. Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma.
Garg AD; Vandenberk L; Koks C; Verschuere T; Boon L; Van Gool SW; Agostinis P
Sci Transl Med; 2016 Mar; 8(328):328ra27. PubMed ID: 26936504
[TBL] [Abstract][Full Text] [Related]
23. [What's next in glioblastoma treatment: Tumor-targeted or immune-targeted therapies?].
Schernberg A; Marabelle A; Massard C; Armand JP; Dumont S; Deutsch E; Dhermain F
Bull Cancer; 2016 May; 103(5):484-98. PubMed ID: 27032303
[TBL] [Abstract][Full Text] [Related]
24. Immunotherapy for glioblastoma: concepts and challenges.
Weiss T; Weller M; Roth P
Curr Opin Neurol; 2015 Dec; 28(6):639-46. PubMed ID: 26402401
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma.
Everson RG; Antonios JP; Lisiero DN; Soto H; Scharnweber R; Garrett MC; Yong WH; Li N; Li G; Kruse CA; Liau LM; Prins RM
Neuro Oncol; 2016 Mar; 18(3):368-78. PubMed ID: 26330563
[TBL] [Abstract][Full Text] [Related]
26. Concepts in glioma immunotherapy.
Platten M; Bunse L; Wick W; Bunse T
Cancer Immunol Immunother; 2016 Oct; 65(10):1269-75. PubMed ID: 27460064
[TBL] [Abstract][Full Text] [Related]
27. PD-L1 expression and prognostic impact in glioblastoma.
Nduom EK; Wei J; Yaghi NK; Huang N; Kong LY; Gabrusiewicz K; Ling X; Zhou S; Ivan C; Chen JQ; Burks JK; Fuller GN; Calin GA; Conrad CA; Creasy C; Ritthipichai K; Radvanyi L; Heimberger AB
Neuro Oncol; 2016 Feb; 18(2):195-205. PubMed ID: 26323609
[TBL] [Abstract][Full Text] [Related]
28. Combining Radiation Therapy with Immune Checkpoint Blockade for Central Nervous System Malignancies.
D'Souza NM; Fang P; Logan J; Yang J; Jiang W; Li J
Front Oncol; 2016; 6():212. PubMed ID: 27774435
[TBL] [Abstract][Full Text] [Related]
29. ReACT Phase II trial: a critical evaluation of the use of rindopepimut plus bevacizumab to treat EGFRvIII-positive recurrent glioblastoma.
Gatson NT; Weathers SP; de Groot JF
CNS Oncol; 2016; 5(1):11-26. PubMed ID: 26670466
[TBL] [Abstract][Full Text] [Related]
30. Is CMV a target in pediatric glioblastoma? Expression of CMV proteins, pp65 and IE1-72 and CMV nucleic acids in a cohort of pediatric glioblastoma patients.
Wakefield A; Pignata A; Ghazi A; Ashoori A; Hegde M; Landi D; Gray T; Scheurer ME; Chintagumpala M; Adesina A; Gottschalk S; Hicks J; Powell SZ; Ahmed N
J Neurooncol; 2015 Nov; 125(2):307-15. PubMed ID: 26341370
[TBL] [Abstract][Full Text] [Related]
31. Assessment of Brain Tumor Response: RANO and Its Offspring.
Eisele SC; Wen PY; Lee EQ
Curr Treat Options Oncol; 2016 Jul; 17(7):35. PubMed ID: 27262709
[TBL] [Abstract][Full Text] [Related]
32. Investigational new drugs for brain cancer.
Staedtke V; Bai RY; Laterra J
Expert Opin Investig Drugs; 2016 Aug; 25(8):937-56. PubMed ID: 27170161
[TBL] [Abstract][Full Text] [Related]
33. Vaccine Therapy, Oncolytic Viruses, and Gliomas.
Desjardins A; Vlahovic G; Friedman HS
Oncology (Williston Park); 2016 Mar; 30(3):211-8. PubMed ID: 26984213
[TBL] [Abstract][Full Text] [Related]
34. Recurrent Glioblastoma: Where we stand.
Roy S; Lahiri D; Maji T; Biswas J
South Asian J Cancer; 2015; 4(4):163-73. PubMed ID: 26981507
[TBL] [Abstract][Full Text] [Related]
35. Immune Evasion Strategies of Glioblastoma.
Razavi SM; Lee KE; Jin BE; Aujla PS; Gholamin S; Li G
Front Surg; 2016; 3():11. PubMed ID: 26973839
[TBL] [Abstract][Full Text] [Related]
36. CAR T Cells Targeting Podoplanin Reduce Orthotopic Glioblastomas in Mouse Brains.
Shiina S; Ohno M; Ohka F; Kuramitsu S; Yamamichi A; Kato A; Motomura K; Tanahashi K; Yamamoto T; Watanabe R; Ito I; Senga T; Hamaguchi M; Wakabayashi T; Kaneko MK; Kato Y; Chandramohan V; Bigner DD; Natsume A
Cancer Immunol Res; 2016 Mar; 4(3):259-68. PubMed ID: 26822025
[TBL] [Abstract][Full Text] [Related]
37. Overview of current immunotherapeutic strategies for glioma.
Calinescu AA; Kamran N; Baker G; Mineharu Y; Lowenstein PR; Castro MG
Immunotherapy; 2015; 7(10):1073-104. PubMed ID: 26598957
[TBL] [Abstract][Full Text] [Related]
38. An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors.
Neagu MR; Reardon DA
Curr Treat Options Oncol; 2015 Nov; 16(11):54. PubMed ID: 26454859
[TBL] [Abstract][Full Text] [Related]
39. Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity.
Caruso HG; Hurton LV; Najjar A; Rushworth D; Ang S; Olivares S; Mi T; Switzer K; Singh H; Huls H; Lee DA; Heimberger AB; Champlin RE; Cooper LJ
Cancer Res; 2015 Sep; 75(17):3505-18. PubMed ID: 26330164
[TBL] [Abstract][Full Text] [Related]
40. CAR therapy: the CD19 paradigm.
Sadelain M
J Clin Invest; 2015 Sep; 125(9):3392-400. PubMed ID: 26325036
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
